Distribution and Elimination of Poly(methyl-2-14C-methacrylate) Nanoparticle Radioactivity after Injection in Rats and Mice

Kreuter, Jörg; Täuber, U.; Illi, Volker

doi:10.1002/jps.2600681129

Cited by 104 publications

(26 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Smaller particles, including nanoparticles, however, can be accumulated in the lung by agglomeration due to breakdown of repulsive forces between the particles. Several studies have demonstrated accumulation of nanoparticles in the lung [15][16][17][18].…”

Section: Passive Targetingmentioning

confidence: 99%

Factors that Control the Circulation Time of Nanoparticles in Blood: Challenges, Solutions and Future Prospects

Yoo

Chambers²,

Mitragotri³

2010

CPD

465

292

View full text Add to dashboard Cite

Numerous types of nanoparticles are being designed for systemic and targeted drug delivery. However, keeping nanoparticles in blood for sufficiently long times so as to allow them to reach their therapeutic target is a major challenge. Upon administration into blood, nanoparticles are quickly opsonized and cleared by the macrophages, thereby limiting their circulation times. Surface-modification of nanoparticles by PEG was developed as the first strategy to prolong nanoparticles circulation. While PEGylation has helped prolong particle circulation, it has several limitations including transient nature of the effect and compromised particle-target interactions. Accordingly, several other approaches have been developed to prolong nanoparticle circulation in blood. These include modification with CD47, modulation of mechanical properties, engineering particle morphology and hitchhiking on red blood cells. In this review, we discuss the factors that affect nanoparticles circulation time and discuss recent progress in development of strategies to prolong circulation time.

show abstract

Section: Passive Targetingmentioning

confidence: 99%

Factors that Control the Circulation Time of Nanoparticles in Blood: Challenges, Solutions and Future Prospects

Yoo

Chambers²,

Mitragotri³

2010

CPD

465

292

View full text Add to dashboard Cite

show abstract

“…These particles could enter the alveoli epithelium by endocytosis and enter the blood or lymphatic system underlying the alveolar epithelium (Oberdorster et al 2005). NPs administered through subcutaneous (Moghimi 2003), intramuscular (Kreuter et al 1979), intradermal (Lee et al 2009), and intraperitoneal (Maincent et al 1992) are absorbed and distributed into the blood circulation. Numerous studies have reported that NPs undergo distribution to different organs and tissues after administration by various routes (Hagens et al 2007).…”

Section: In Vivo Fate Of Biodegradable Nanoparticlesmentioning

confidence: 98%

Biodegradable Nanoparticles and Their In Vivo Fate

Kumari

Singla

Guliani

et al. 2016

Nanoscale Materials in Targeted Drug Delivery, Theragnosis and Tissue Regeneration

View full text Add to dashboard Cite

Biodegradable nanoparticles (BNPs) are seeking augmented attention for their ability to serve as a carrier for site-specific delivery of drugs, biomolecules, proteins and peptides in the body. They offer enhanced biocompatibility, better drug encapsulation and sustained release profile of a great number of drugs and biomolecules to be used in a variety of applications in nanomedicine. The use of BNPs for controlled drug delivery has shown significant therapeutic potential. Concurrently, targeted delivery technologies are becoming an increasingly important area of scientific investigation. The fate of BNPs is decided by virtue of their physiochemical properties in biological medium. Another important area which is gaining attention of researchers is the behaviour of BNPs in biological milieu. In the present chapter, efforts are made to give the readers a comprehensive outlook of the topic covering the following major points: (1) brief introduction to BNPs; (2) synthesis methodologies of BNPs; (3) characterisation of BNPs; (4) BNPs for drug delivery; (5) drug release mechanisms from BNPs; (6) targeted drug delivery using BNPs; (7) biological barriers encountered by BNPs; and (8) in vivo fate of BNPs.

show abstract

“…For use as carriers the synthesis of numerous synthetic and biological macromolecules is possible, like polyacrylates, polyamides, polystyrenes, cyanoacrylates, polyethylenes, polymers of lactic acid and also their copolymers with glycolic acid respectively [278][279][280][281][282][283]. As biological carrier systems fibronectin, cellulose, polysaccharides, albumin and collagen were used.…”

Section: Formulations For Optimizing Resorptionmentioning

confidence: 99%

Development and Characterization of Drug Delivery Systems for Targeting Mammalian Cells and Tissues: A Review

Braun

Pipkorn²,

Waldeck

2005

CMC

View full text Add to dashboard Cite

Recent advances in the development of diagnostics and therapeutics in the fields of recombinant biochemistry, solid phase peptide synthesis as well as in galenical research have resulted in highly specific and efficient components. Presently, millions of patients can profit from these new therapeutic modalities. The application of an effective anti-tumor dose of drugs can lead to marked toxicity in patients. Therefore, safe and efficient possibilities to transport these compounds to the target are of outmost importance. The importance of drug delivery is pivotal in the wide area of pharmacological research. However, until now, this issue is still to be solved. The main goal of every drug delivery system is the delivery of a precise amount of a drug at a pre-programmed rate to the desired location in order to achieve the necessary drug concentration in the targeted organ for effective treatment. The key problem still remains the achievement of curative doses in a pharmacologically active state in the desired target while avoiding side effects. Although respectable advances can be recognized in this field, the currently applied mechanisms for the transport of therapeutic molecules across biological membranes still remain far from being efficient. Helper molecules could improve delivery to desired target sites. Presently, a number of efforts are made and a huge spectrum of biochemical, biological, medical, pharmaceutical and physical possibilities are arising. However, the design and development of successful therapies based on this technology still remains a great challenge.

show abstract

Distribution and Elimination of Poly(methyl-2-14C-methacrylate) Nanoparticle Radioactivity after Injection in Rats and Mice

Cited by 104 publications

References 10 publications

Factors that Control the Circulation Time of Nanoparticles in Blood: Challenges, Solutions and Future Prospects

Factors that Control the Circulation Time of Nanoparticles in Blood: Challenges, Solutions and Future Prospects

Biodegradable Nanoparticles and Their In Vivo Fate

Development and Characterization of Drug Delivery Systems for Targeting Mammalian Cells and Tissues: A Review

Contact Info

Product

Resources

About